Gut Hormones in Metabolic Disease Research
Advance Metabolic Research with Gut Hormone Assays
Gut hormones play a key role in metabolic disease research. Discover how Mercodia’s assays support precision and innovation in therapies for obesity, diabetes, and liver disease.
Biomarkers for obesity, diabetes, MASLD & MASH
Therapies and treatments have been developed and continue to evolve in recent years, aiming to treat and help patients suffering from various metabolic-related diseases. Multiple hormone-based therapies for individuals suffering from obesity, type 2 diabetes, metabolic-associated steatotic liver disease (MASLD), and metabolic-associated steatohepatitis (MASH), to mention some, have reached the top and remain in the spotlight.
From molecules to mechanisms: The power of biomarkers
To fully understand the mechanism of action and signalling pathways of treatments, as well as for exploratory purposes to discover possible new applications, complete biomarker panels must be analyzed, and specific and valuable molecules must be studied.
GLP-1 & GIP: Key targets in therapy development
When performing studies for the development of new therapies for metabolic-related diseases, it is important to understand the role the targets play and the impact they have in regulating appetite and energy homeostasis, controlling glucose metabolism and insulin secretion, and modulating metabolic pathways related to both liver fat accumulation and inflammation.
Why measure GLP-1 and GIP?
Understanding how GLP-1 and GIP, interact across different organs and systems helps researchers understand how targeting multiple receptors at once can deliver combined benefits, such as lower food intake, improved blood sugar control, support healthy fat metabolism, and protect the heart and brain, as illustrated in Figure 1. This broader perspective strengthens the development of more effective treatments for obesity and other metabolic diseases, while also highlighting the value of these hormones as key biomarkers for personalized healthcare.
- Better comprehension of obesity treatment and their potential as biomarkers for personalized care.
- Valuable insights into the effectiveness of the therapy, understanding glucose control, insulin response, appetite regulation, fat metabolism, and therapy benefits
- Deeper knowledge into metabolic dysregulation, insulin resistance, and inflammatory processes contributing to liver disease.
- Awareness of improved or altered glycemic control, reduced liver fat, and weight management.
Fig 1. An illustration showing the metabolic actions of glucagon, GLP-1, and GIP on key target organs, with a focus on their functions related to metabolic disorders.
Explore Mercodia’s Gut Hormone Assay Portfolio
At Mercodia, we offer high-quality immunoassays for GLP-1, GIP, and other key metabolic markers, empowering researchers and clinicians with the tools they need to drive innovation and precision in metabolic health.
GLP-1 (Total) ELISA (10-1278-01)
The Mercodia Total GLP-1 ELISA provides a chemiluminescent method for the quantitative determination of amidated GLP-1 in human plasma and serum samples. The assay has been certified according to CLSI, FDA, and EMA guidelines.
GIP (Total) ELISA (10-1258-01)
The Mercodia Total GIP ELISA provides a method for the quantitative determination of total GIP in human samples. Total GIP ELISA has no cross-reactivity to known cross-reactants such as GLP-1, glucagon, oxyntomodulin, and glicentin.
